PillRx only · Capsule · Oral
Lisdexamfetamine Dimesylate Capsules
Lisdexamfetamine Dimesylate
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US7 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 7 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$2.780
Latest avg · Jul 22, 2026
-14%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
8.9K
Rx · 2026 Q1
261K
Units dispensed
-67%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Solco Healthcare US, LLC | unknown | 7 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jul 14, 2023SHORTAGEDrug shortage: Lisdexamfetamine Dimesylate Capsule (Solco Healthcare US, LLC)
Lisdexamfetamine Dimesylate Capsule — reported in shortage by Solco Healthcare US, LLC. Therapeutic category: Psychiatry.